GSG Advisors’s AbbVie ABBV Stock Holding History

GSG Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$553K	Buy	2,197 +36	+2%	+$7.75K	0.12%	81
2026 Q1	$470K	Buy	2,161 +99	+5%	+$22K	0.12%	78
2025 Q4	$471K	Buy	2,062 +859	+71%	+$196K	0.12%	73
2025 Q3	$294K	Buy	1,203 +25	+2%	+$5.09K	0.08%	101
2025 Q2	$219K	Buy	+1,178	New	+$219K	0.06%	109

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

GSG Advisors's ABBV Position: Q2 2026 in Review

GSG Advisors increased its AbbVie (ABBV) stake by 1.7% in Q2 2026, buying an estimated $7.75K and bringing the position to 2,197 shares worth $553K. The position accounts for 0.12% of the portfolio, ranked #81.

GSG Advisors first reported a position in ABBV in Q2 2025 and has held it in 5 quarters since. 4,214 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

GSG Advisors held 2,197 shares of AbbVie worth $553K as of Q2 2026.
GSG Advisors bought 36 AbbVie shares in Q2 2026, an estimated $7.75K.
AbbVie made up 0.12% of GSG Advisors's portfolio in Q2 2026, its #81 holding.
GSG Advisors first reported a position in AbbVie in Q2 2025 and has held it in 5 quarters since.
4,214 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on GSG Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.